Overview
Rani Therapeutics develops an oral delivery platform that turns biologic drugs, usually given by injections, into swallowable capsules. The capsules use protective coatings and formulation strategies to survive the digestive tract and release the medicine so it works like an injection. The company differentiates itself by partnering with pharmaceutical companies to license and commercialize this oral delivery technology, rather than competing solely on drugs. Its goal is to make biologic treatments easier to take, improve patient adherence, and broaden access by bringing capsule-based biologics to market.
Work here?Claim your company
About Rani Therapeutics
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
San Jose, CA
Founded
2012
Get referred to Rani Therapeutics
See people who can refer or advise you
Simplify's take
What believers are saying
- RT-114 Phase 1a showed over 150% bioavailability versus matched subcutaneous PG-102.
- Rani expects additional RT-114 data by year-end 2026 and Phase 1B in 2027.
- Q3 2026 contract revenue reached $1.7 million, driven by Chugai collaboration milestones.
What critics are saying
- Nasdaq issued a bid-price deficiency on May 11, 2026; delisting risk persists after November 9.
- Rani reported only $45.3 million cash on September 30, 2026, after $8.8 million quarterly loss.
- The capital structure carries massive dilution from 77.4 million pre-funded warrants and additional options.
What makes Rani Therapeutics unique
- RaniPill converts injectable biologics into swallowable small-intestine dosing without electronics.
- FDA accepted RaniPill into the Emerging Technology Program in October 2026.
- Chugai, ProGen, and PegBio validate RaniPill across hemophilia, obesity, and metabolic programs.
Help us improve and share your feedback! Did you find this helpful?
Funding
Total Funding
$391.8M
Above
Industry Average
Funded Over
11 Rounds
Stock Price
Growth & Insights and Company News
6 month growth
0%1 year growth
1%2 year growth
-2%Rani Therapeutics reported a third-quarter net loss of $8.8 million, up from $7.9 million a year earlier. The clinical-stage company, which develops oral delivery of biologics, said cash and marketable securities stood at $45.3 million on September 30, 2026, down from $53.4 million in June. It expects that to fund operations at least through the end of 2027. Contract revenue was $1.7 million, against none a year earlier, mainly from its deal with Chugai. Research and development spending rose to $6.0 million from $3.2 million. In October, the US Food and Drug Administration accepted the company's RaniPill platform into its Emerging Technology Program, allowing early talks on technical and regulatory issues. Rani is enrolling 15 more healthy volunteers in a Phase 1a study of RT-114, with data expected by the end of 2026.
Rani Therapeutics eyes 2027 obesity data as oral biologics platform advances. October 21, 2026 Key points. * Rani Therapeutics' RaniPill platform is designed to deliver biologics, peptides and other large molecules into the small intestine, with the company reporting more than 250 devices administered across four clinical studies. * Its RT-114 obesity program, an oral version of ProGen's PG-102 GLP-1/GLP-2 agonist, achieved more than 150% bioavailability versus a matched subcutaneous dose in a 30-person Phase 1 study. Rani plans to start a repeat-dose Phase 1B trial by year-end, with data expected in 2027. * Rani ended June with $53 million in cash and securities and expects its runway to extend through the fourth quarter of 2027. The company is also pursuing milestone-generating collaborations with Chugai and PegBio, including a potential Chugai milestone report in 2027. * Tracking Rani Therapeutics through earnings season? MarketBeat All Access sends real-time alerts on ratings, earnings, and news - $149 a year, locked in for as long as you stay. Rani Therapeutics NASDAQ: RANI outlined progress for its oral biologics delivery platform, including plans to advance its obesity program RT-114 and expectations for additional milestones from its collaboration with Chugai. Chief Executive Officer Talat Imran said the clinical-stage biotechnology company has developed a swallowable device designed to deliver biologic medicines in the small intestine with bioavailability comparable to subcutaneous injection. The RaniPill is intended to administer biologics including monoclonal antibodies, proteins, peptides and oligonucleotides orally. According to Imran, the device functions as a "swallowable auto-injector." After reaching the small intestine, an effervescent reaction inflates and aligns a balloon containing a microsyringe. The syringe injects the drug into the intestinal wall, where Imran said there are no sharp pain receptors. The needle dissolves after administration, while the deflated balloon is excreted. Imran said Rani has completed four clinical studies, including a repeat-dose study, and has administered more than 250 RaniPills. He said the company has delivered drugs including STELARA and factor VIII in human studies. RT-114 obesity program. Chief Business Officer Kate McKinley discussed Rani's partnership with South Korea-based ProGen to develop RT-114, an oral version of ProGen's PG-102, a GLP-1/GLP-2 dual agonist. The companies share development costs equally, jointly own intellectual property and will split future revenue. ProGen holds rights in Asia, while Rani holds rights in the U.S., Europe, the U.K., Australia and Canada. McKinley said Rani's Phase 1 study in 30 healthy volunteers showed PG-102 delivered through the RaniPill achieved bioavailability greater than 150% of a matched 12-milligram subcutaneous dose. The study used the same dose in both the oral and subcutaneous arms, she said, and reported no device-related adverse events. The company said exposure was not variable between treatment arms or among patients. Reported adverse events were consistent with the drug class and were mild to moderate, transient gastrointestinal events, McKinley said. Rani plans to add 15 volunteers to the Phase 1A study. Those participants will receive two 12-milligram RaniPill doses, for a total dose of 24 milligrams. The expansion is intended to further characterize the relationship between oral and subcutaneous pharmacokinetics and help determine dosing for a Phase 1B trial. The Phase 1B repeat-dose obesity study is expected to begin by the end of the year, with data anticipated in 2027. McKinley said Rani believes an oral, weekly version of PG-102 could offer competitive weight loss with a potentially more tolerable adverse-event profile than other obesity therapies, though the company did not provide a target weight-loss figure. Discover more Save on Rx Imran said ProGen's subcutaneous data have suggested faster titration and lower rates of nausea and vomiting than other incretin therapies. He also cited potential preservation of lean body mass as a feature that ProGen plans to evaluate further in future studies. Additional partnerships and platform strategy. Rani also highlighted its agreement with Chugai involving an antibody program in development for hemophilia. The arrangement included $10 million upfront, up to $18 million in technology-transfer payments, $57 million in development milestones, $100 million in sales milestones and single-digit royalties, according to the discussion. Chugai also has options on up to five additional targets. McKinley said certain early Chugai milestones are tied to Rani's platform and manufacturing progress. While the company did not provide exact timing, she said Rani expects to report on at least one milestone in 2027. The company also entered a collaboration with PegBio covering obesity and metabolic molecules. McKinley said PegBio has an approved GLP product in China and a pipeline that includes penta-agonists, tri-agonists, a MariTide-like drug and siRNA programs. Rani expects to test multiple partner compounds through its delivery platform and potentially seek additional partners or further invest in selected programs. Cash runway and manufacturing. Chief Financial Officer Nic Maestas said Rani ended June with $53 million in cash and securities following a $20 million registered direct offering led by a sovereign wealth fund. The company's current cash runway guidance extends through 2027. Maestas said Rani had previously projected runway into 2028 after its October 2025 financing and Chugai agreement, then updated guidance in March to the fourth quarter of 2027. He attributed the revisions to increased investment in the platform, debt retirement and a more conservative approach to excluding anticipated Chugai milestone payments from current runway guidance. Imran said the RaniPill was designed without electronics and uses materials including plastic, sugar and effervescent components. He said the company expects manufacturing costs to decline with scale, particularly for high-volume obesity programs. He also said partner-funded development and potential upfront and milestone payments from future option exercises could help support the company's pipeline. About Rani Therapeutics (NASDAQ:RANI). Rani Therapeutics Holdings, Inc is a biotechnology company developing oral delivery technologies for biologic medicines that are typically administered by injection. The company's platform is designed to transport therapeutic molecules through the stomach and release them in the small intestine, where they can be absorbed into the bloodstream. Its primary technology, the RaniPill capsule, is a robotic oral delivery system intended to deliver biologics, peptides and other large-molecule therapies. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Rani Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list. While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. The space race is growing fast, and you don't have to have gotten in early on SpaceX to profit. This report shows seven space stocks you can buy today that may grow as rockets, satellites, defense, space internet, and new space technology become more important. Continue following MarketBeat
Rani Therapeutics (NASDAQ:RANI) shares climb 1.5% - here's what happened. October 16, 2026 Key points. * Rani Therapeutics shares rose 1.5% to $0.68 in mid-day trading, though trading volume was 21% below the stock's average. The company has a market capitalization of approximately $94.8 million. * Analyst sentiment remains generally positive, with a consensus rating of "Moderate Buy" and an average price target of $8.75, despite one sell rating. * Rani exceeded its latest quarterly expectations, reporting a loss of $0.04 per share versus a forecasted $0.05 loss and revenue of $1.71 million versus estimates of $0.93 million. CEO Talat Imran also increased his stake by purchasing 35,000 shares. * Five stocks we like better than Rani Therapeutics. Rani Therapeutics Holdings, Inc. (NASDAQ:RANI - Get Free Report) shares were up 1.5% during mid-day trading on Thursday. The stock traded as high as $0.6943 and last traded at $0.68. 450,210 shares were traded during mid-day trading, a decline of 21% from the average daily volume of 572,240 shares. The stock had previously closed at $0.6702. Analyst upgrades and downgrades. Several research firms recently commented on RANI. HC Wainwright reaffirmed a "buy" rating on shares of Rani Therapeutics in a report on Tuesday, October 6th. Weiss Ratings lowered Rani Therapeutics from a "sell (d-)" rating to a "sell (e+)" rating in a report on Friday, July 17th. Finally, Chardan Capital upgraded Rani Therapeutics to a "strong-buy" rating in a research report on Wednesday, August 26th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $8.75. Rani Therapeutics trading up 1.5%. The company has a market cap of $94.79 million, a PE ratio of -2.52 and a beta of 0.69. The business has a fifty day moving average of $0.81 and a 200-day moving average of $0.83. Rani Therapeutics (NASDAQ:RANI - Get Free Report) last released its quarterly earnings results on Thursday, August 13th. The company reported ($0.04) earnings per share for the quarter, beating the consensus estimate of ($0.05) by $0.01. The company had revenue of $1.71 million during the quarter, compared to the consensus estimate of $0.93 million. As a group, research analysts predict that Rani Therapeutics Holdings, Inc. will post -0.17 EPS for the current year. Insider activity at Rani Therapeutics. In related news, CEO Talat Imran acquired 35,000 shares of Rani Therapeutics stock in a transaction that occurred on Friday, July 17th. The stock was bought at an average price of $0.72 per share, with a total value of $25,200.00. Following the transaction, the chief executive officer directly owned 469,736 shares in the company, valued at approximately $338,209.92. This represents a 8.05% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. 26.73% of the stock is currently owned by corporate insiders. Hedge funds weigh in on Rani Therapeutics. Several hedge funds and other institutional investors have recently added to or reduced their stakes in RANI. AWM Investment Company Inc. purchased a new position in Rani Therapeutics in the 2nd quarter worth about $5,703,000. Squarepoint Ops LLC increased its position in Rani Therapeutics by 155.5% during the second quarter. Squarepoint Ops LLC now owns 41,902 shares of the company's stock valued at $32,000 after acquiring an additional 25,501 shares during the last quarter. Finally, Kestra Private Wealth Services LLC boosted its position in Rani Therapeutics by 4.1% in the first quarter. Kestra Private Wealth Services LLC now owns 265,159 shares of the company's stock worth $195,000 after purchasing an additional 10,347 shares during the last quarter. 30.19% of the stock is owned by institutional investors. About Rani Therapeutics. Rani Therapeutics Holdings, Inc is a biotechnology company developing oral delivery technologies for biologic medicines that are typically administered by injection. The company's platform is designed to transport therapeutic molecules through the stomach and release them in the small intestine, where they can be absorbed into the bloodstream. Discover more Research tools subscription MarketBeat All Access Stock Average Calculator Its primary technology, the RaniPill capsule, is a robotic oral delivery system intended to deliver biologics, peptides and other large-molecule therapies. Further reading. This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected]. Before you consider Rani Therapeutics, you'll want to hear this. MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Rani Therapeutics wasn't on the list. While Rani Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys. Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets. Continue following MarketBeat
Rani Therapeutics to participate in the Chardan Healthcare Conference. SAN JOSE, Calif., Oct. 13, 2026 (GLOBE NEWSWIRE) - Rani Therapeutics Holdings, Inc (Nasdaq: RANI), a clinical-stage biotherapeutics company focused on oral delivery of biologics, today announced that the company's management team will participate in a fireside chat at the upcoming Chardan Healthcare Conference. Details below: Chardan Healthcare Conference Date: Tuesday, October 20, 2026 at 1:00pm E.T. Location: New York, New York Presenter: Chief Executive Officer, Talat Imran, Chief Financial Officer, Nicholas Maestas, and Chief Business Officer, Kate McKinley Format: Fireside Chat and 1x1 Meetings Interested parties can access the live webcast for this conference from the Investor Relations section of the company's website at www.ranitherapeutics.com. The webcast replay will be available after the conclusion of the presentation. About Rani Therapeutics Rani Therapeutics is a clinical-stage biotherapeutics company focused on advancing technologies to enable the development of orally administered biologics and drugs. Rani has developed the RaniPill(R) capsule, a novel, proprietary and patented platform technology, intended to replace subcutaneous injection or intravenous infusion of biologics and drugs with oral dosing. Rani has successfully conducted several preclinical and clinical studies to evaluate safety, tolerability and bioavailability using RaniPill(R) capsule technology.
Rani Therapeutics posts Q2 loss and strengthens cash. (Moderate) Rhea-AI filing summary. Rani Therapeutics Holdings, Inc. reported for the period ended June 30, 2026 that it remains a clinical-stage company developing its RaniPill oral biologics platform, with two configurations, RaniPill GO and high-capacity RaniPill HC. Contract revenue reached $1.7 million in the quarter and $3.4 million year-to-date, primarily from a Chugai collaboration, compared with minimal revenue a year earlier. Operating expenses were $10.5 million for the quarter and $20.6 million for the first six months. Net loss was $8.4 million for the quarter and $16.4 million year-to-date. Cash, cash equivalents and marketable securities totaled $53.4 million, and the company states this should fund operations for at least twelve months from issuance of these financial statements. In May 2026 it raised $20.0 million gross through a Class A share and pre-funded warrant financing. Rani continues its RT-114 obesity program with ProGen and reported Phase 1a data showing RT-114 oral delivery achieved bioavailability exceeding 150% versus a matched subcutaneous dose. Filing explained. Issued shares increased, while immediately exercisable pre-funded warrants and a new share reserve add further potential issuance capacity. This Form 10-Q is an unaudited quarterly report updating Rani Therapeutics' financial position, liquidity and risks for the period ended June 30, 2026. The material holder-facing change is that the May financing had already issued 12,476,637 Class A shares, while 6,214,953 pre-funded warrants remained outstanding at that date and could convert into additional shares. Those May pre-funded warrants were immediately exercisable at $0.0001 per share and had no expiration date, creating additional share-issuance capacity rather than shares already issued. The filing also reports 80,266,667 pre-funded warrants from the October financing outstanding at June 30, 2026. After quarter-end, purchasers exercised 2,910,000 of those October pre-funded warrants in July, leaving 77,357,166 outstanding; the filing reports only de minimis proceeds from that exercise. Separately, the board reserved 5,500,000 shares under a new equity inducement plan, which is authorization for potential awards rather than a reported issuance. The company also gave notice on June 24, 2026 to end the occupancy portion of its San Jose related-party service arrangement effective December 31, 2026; total undiscounted future minimum operating-lease payments reported at quarter-end were $4,043 thousand. Key figures. Contract revenue YTD: $3,416 (thousands) Net loss YTD: $16,436 (thousands) Cash and cash equivalents: $4,868 (thousands) +5 more Key terms. RaniPill HC, pre-funded warrants, deferred revenue, Collaborative Arrangements, +1 more Earnings snapshot. Contract revenue: $1,708 (thousands) for the quarter; $3,416 (thousands) YTD Three and six months ended June 30, 2026 Faq. How much revenue did Rani Therapeutics (RANI) generate in the June 30, 2026 quarter? Rani reported $1.7 million in contract revenue for the quarter, and $3.4 million for the six months ended June 30, 2026. This revenue is primarily from its Chugai collaboration related to the RaniPill HC technology transfer. What was Rani Therapeutics' (RANI) net loss for the six months ended June 30, 2026? Rani recorded a net loss of $16.4 million for the six months ended June 30, 2026. This reflects ongoing research and development and general and administrative expenses as the company advances its RaniPill platform and clinical programs. What is Rani Therapeutics' (RANI) cash and investment position as of June 30, 2026? As of June 30, 2026, Rani held $4.9 million in cash and cash equivalents and $48.5 million in marketable securities, totaling $53.4 million. The company states this is sufficient to fund operations for at least twelve months from the financial statement issuance date. What financing did Rani Therapeutics (RANI) complete in May 2026? In May 2026, Rani entered a securities purchase agreement issuing 12,476,637 Class A shares and 6,214,953 pre-funded warrants, for $20.0 million in gross proceeds. The pre-funded warrants have a $0.0001 exercise price and no expiration date. What are the key details of Rani Therapeutics' (RANI) Chugai collaboration? Under the Chugai collaboration, Rani received a $10.0 million upfront payment and may earn up to $18.0 million in technology transfer milestones, $57.0 million in regulatory and development milestones, and $100.0 million in sales-based milestones, plus single-digit royalties. What Phase 1 data did Rani Therapeutics (RANI) report for RT-114? On July 15, 2026, Rani reported initial Phase 1a data showing oral RT-114 achieved bioavailability exceeding 150% relative to a matched subcutaneous 12 mg dose of PG-102, with an elimination half-life of 5.6 days in healthy volunteers. AI-generated analysis. How Rhea-AI works. Not financial advice. Don't miss StockTitan's market coverage in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google Available on EDGAR 08/13/2026 - 04:18 PM Accepted by SEC EDGAR 08/13/2026 - 04:16 PM
There are no jobs for Rani Therapeutics right now.
Find jobs on Simplify and start your career today
We update Rani Therapeutics's jobs every few hours, so check again soon!Browse all jobs
About Rani Therapeutics
Industries
Company Size
51-200
Company Stage
IPO
Headquarters
San Jose, CA
Founded
2012
There are no jobs for Rani Therapeutics right now.
Find jobs on Simplify and start your career today
We update Rani Therapeutics's jobs every few hours, so check again soon!Browse all jobs